Belzutifan

Phase 2Recruiting

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Pheochromocytoma/Paraganglioma

Conditions

Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor, HIF-2α Mutated Cancers

Trial Timeline

Aug 12, 2021 → Jun 4, 2029

NCT ID

NCT04924075

About Belzutifan

Belzutifan is a phase 2 stage product being developed by Merck for Pheochromocytoma/Paraganglioma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04924075. Target conditions include Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06677190	Phase 2	Recruiting	Dec 20, 2024	Jun 30, 2029	Ovarian Cancer
NCT04994522	Phase 1	Completed	Jul 12, 2022	Apr 11, 2024	End Stage Renal Disease
NCT04995484	Phase 1	Completed	Jun 24, 2022	Jan 3, 2024	Moderate Hepatic Impairment
NCT04924075	Phase 2	Recruiting	Aug 12, 2021	Jun 4, 2029	Pheochromocytoma/Paraganglioma
NCT04846920	Phase 1	Active	Jun 14, 2021	Jul 21, 2026	Carcinoma, Renal Cell
NCT04489771	Phase 2	Active	Sep 13, 2020	Oct 4, 2026	Carcinoma, Renal Cell
NCT03401788	Phase 2	Active	May 2, 2018	Mar 29, 2026	VHL - Von Hippel-Lindau Syndrome
NCT03445169	Phase 1	Completed	Feb 23, 2018	May 26, 2018	Healthy
NCT02974738	Phase 1	Active	Dec 7, 2016	Apr 14, 2027	Advanced Solid Tumors

Other Products from Merck

DuleraApproved

ImipenemApproved

Mavenclad®Approved

raltegravir + PlaceboApproved

alendronate sodiumApproved